After more than a decade of foundational studies involving protease-activated receptors (PARs), the firm Function Therapeutics, Inc. was founded to advance a new class of PAR-targeting anti-inflammatories to the clinic. The original partnership between the labs of Dr. Robert Flaumenhaft (Harvard Medical School) and Dr. Chris Dockendorff (previously at Marquette Univ.) is the foundation for an integrated team of executives, consultants, and collaborators with decades of experience in disease biology, structural biology, medicinal chemistry, and pharmacology.
